Head to Head Contrast: TRACON Pharmaceuticals (NASDAQ:TCON) vs. Tevogen Bio (NASDAQ:TVGN)

TRACON Pharmaceuticals (NASDAQ:TCON) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

TRACON Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for TRACON Pharmaceuticals and Tevogen Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TRACON Pharmaceuticals	0	1	0	0	2.00
Tevogen Bio	0	0	1	0	3.00

TRACON Pharmaceuticals currently has a consensus price target of $60.00, indicating a potential upside of 57,042.86%. Tevogen Bio has a consensus price target of $4.20, indicating a potential upside of 955.28%. Given TRACON Pharmaceuticals’ higher probable upside, research analysts clearly believe TRACON Pharmaceuticals is more favorable than Tevogen Bio.

Profitability

This table compares TRACON Pharmaceuticals and Tevogen Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TRACON Pharmaceuticals	N/A	-237.65%	57.29%
Tevogen Bio	N/A	-387.78%	434.75%

Earnings & Valuation

This table compares TRACON Pharmaceuticals and Tevogen Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TRACON Pharmaceuticals	$12.05 million	0.03	-$3.59 million	$0.67	0.16
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A

Tevogen Bio has lower revenue, but higher earnings than TRACON Pharmaceuticals.

Insider & Institutional Ownership

11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.